Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker

Figure 2

Expression of the GINS2 gene in different cancer types and pathological tumour stages. (a) Analysis of GINS2 mRNA expression in different tumours by TIMER2. ; ; . (b) Differential mRNA expression of GINS2 in ACC, DLBC, LAML, OV, SARC, SKCM, THYM, and UCS versus the corresponding nontumour tissues in TCGA dataset. The box chart data are provided. . (c) The protein expression levels of GINS2 were analyzed in tumour and paracancerous tissues of several cancers (BRCA, GBM, hepatocellular carcinoma, HNSC, LUAD, OV, PAAD, and UCEC) by the CPTAC dataset. (d) In addition, the differences in GINS2 expression levels were analyzed in the pathological stages of different tumours (ACC, HNSC, KICH, KIRC, KIRP, LIHC, LUAD, and TGCT). Log2 (TPM+1) was used for logarithmic analysis. (e) GINS2 mutation frequency in human cancers according to data on the cBioPortal database.

(a)

(b)

(c)

(d)

(e)